Journal article
A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis
P Foley, S Garrett, L Ryttig
Current Medical Research and Opinion | TAYLOR & FRANCIS LTD | Published : 2018
Abstract
Background: Calcipotriol 50 µg/g and betamethasone 0.5 mg/g dipropionate (Cal/BD) aerosol foam formulation provides greater effectiveness and improved patient preference compared with traditional Cal/BD formulations for the topical treatment of plaque psoriasis. Objective: To determine the cost-effectiveness of Cal/BD foam compared with Cal/BD gel from the Australian perspective. Methods: A Markov model was developed to evaluate the cost-effectiveness of topical Cal/BD foam and gel for the treatment of people with plaque psoriasis. Treatment effectiveness, safety, and utilities were based on a randomized control trial, resource use was informed by expert opinion, and unit costs were obtained..
View full abstractGrants
Funding Acknowledgements
P.F. has disclosed grant and personal fees from AbbVie, Amgen, Celgene, LEO, Lilly, Janssen, Novartis, Merck, Valeant, Galderma, Roche, and Sanofi. P.F. has also acted as an investigator in clinical trials for AbbVie, Merck, Valeant, UCB, BMS, Galderma, Gentech, GSK, Roche, Sanofi, Amgen, Celgene, LEO, Lilly, Janssen, and Boehringer Ingelheim. P.F. has received personal fees from Sun Pharma, UCB, and GSK. S.G. reports being contracted to deliver health economics services for publications from the Pharmaceutical Benefits Advisory Committee. L.R. is an employee of LEO Pharma. Peer reviewers on this manuscript have received an honorarium from CMRO for their review work. Two peer-reviewers have disclosed considerable support from Leo and from other companies that make products for psoriasis, and funding support from Johnson and Johnson, respectively.